Katrin Holzwarth

786 total citations
15 papers, 601 citations indexed

About

Katrin Holzwarth is a scholar working on Urology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Katrin Holzwarth has authored 15 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Urology, 6 papers in Dermatology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Katrin Holzwarth's work include Hair Growth and Disorders (7 papers), Autoimmune Bullous Skin Diseases (5 papers) and Dermatology and Skin Diseases (5 papers). Katrin Holzwarth is often cited by papers focused on Hair Growth and Disorders (7 papers), Autoimmune Bullous Skin Diseases (5 papers) and Dermatology and Skin Diseases (5 papers). Katrin Holzwarth collaborates with scholars based in United States, Japan and Germany. Katrin Holzwarth's co-authors include Jonathan Janes, Margaret Gamalo, Brett King, Eric L. Simpson, Fabio P. Nunes, Yves Dutronc, Seth Forman, Robert Bissonnette, Guanglei Yu and Jill Shwed McCollam and has published in prestigious journals such as The EMBO Journal, Journal of Investigative Dermatology and Personality and Individual Differences.

In The Last Decade

Katrin Holzwarth

15 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katrin Holzwarth United States	10	355	196	130	128	103	15	601
Patrizia Teofoli Italy	16	291 0.8×	83 0.4×	32 0.2×	278 2.2×	152 1.5×	32	769
Makoto Hashiro Japan	10	242 0.7×	87 0.4×	18 0.1×	74 0.6×	56 0.5×	21	488
O.P. Kreyden Switzerland	12	273 0.8×	172 0.9×	12 0.1×	140 1.1×	103 1.0×	25	618
Dalia Pickholtz Israel	6	62 0.2×	63 0.3×	15 0.1×	68 0.5×	169 1.6×	6	493
Kenichi Isoda Japan	13	169 0.5×	28 0.1×	17 0.1×	36 0.3×	40 0.4×	45	499
M Lacour United Kingdom	9	223 0.6×	131 0.7×	16 0.1×	30 0.2×	76 0.7×	26	486
Jennifer E. Hundt Germany	12	69 0.2×	18 0.1×	39 0.3×	108 0.8×	56 0.5×	42	413
Dariush Honardoust Canada	10	257 0.7×	27 0.1×	101 0.8×	17 0.1×	21 0.2×	13	577
Kari Paukkonen Finland	14	121 0.3×	70 0.4×	12 0.1×	240 1.9×	208 2.0×	19	546
Gysbert van Setten Sweden	12	130 0.4×	199 1.0×	11 0.1×	17 0.1×	24 0.2×	23	902

Countries citing papers authored by Katrin Holzwarth

Since Specialization

Citations

This map shows the geographic impact of Katrin Holzwarth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katrin Holzwarth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katrin Holzwarth more than expected).

Fields of papers citing papers by Katrin Holzwarth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katrin Holzwarth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katrin Holzwarth. The network helps show where Katrin Holzwarth may publish in the future.

Co-authorship network of co-authors of Katrin Holzwarth

This figure shows the co-authorship network connecting the top 25 collaborators of Katrin Holzwarth. A scholar is included among the top collaborators of Katrin Holzwarth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katrin Holzwarth. Katrin Holzwarth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Senna, Maryanne M., Arash Mostaghimi, Manabu Ohyama, et al.. (2024). Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal of the European Academy of Dermatology and Venereology. 38(3). 583–593. 21 indexed citations

King, Brett, Arash Mostaghimi, Yutaka Shimomura, et al.. (2024). 51436 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 2.3 years and up to 4 Years of Exposure. Journal of the American Academy of Dermatology. 91(3). AB82–AB82. 1 indexed citations

King, Brett, Justin Ko, Bianca Maria Piraccini, et al.. (2023). 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure. Journal of the American Academy of Dermatology. 89(3). AB220–AB220. 1 indexed citations

King, Brett, Arash Mostaghimi, Yutaka Shimomura, et al.. (2022). Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal of Dermatology. 188(2). 218–227. 37 indexed citations

Bieber, Thomas, Norito Katoh, Eric L. Simpson, et al.. (2022). Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. Journal of Dermatological Treatment. 34(1). 2161812–2161812. 32 indexed citations

King, Brett, Arash Mostaghimi, Yutaka Shimomura, et al.. (2022). 33966 Integrated safety analysis of baricitinib in adults with severe alopecia areata from 2 randomized clinical trials. Journal of the American Academy of Dermatology. 87(3). AB176–AB176. 1 indexed citations

King, Brett, Catherine Maari, Edward Lain, et al.. (2021). Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. American Journal of Clinical Dermatology. 22(3). 395–405. 32 indexed citations

Simpson, Eric L., Seth Forman, Jonathan I. Silverberg, et al.. (2021). Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). Journal of the American Academy of Dermatology. 85(1). 62–70. 106 indexed citations

King, Brett, Justin Ko, Seth Forman, et al.. (2021). Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study. Journal of the American Academy of Dermatology. 85(4). 847–853. 90 indexed citations

10.

Maari, Catherine, Edward Lain, Jonathan I. Silverberg, et al.. (2021). 27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials. Journal of the American Academy of Dermatology. 85(3). AB127–AB127. 1 indexed citations

11.

King, Brett, Ohsang Kwon, Natasha Atanaskova Mesinkovska, et al.. (2021). LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1). Journal of Investigative Dermatology. 141(9). B18–B18. 3 indexed citations

12.

Bieber, Thomas, Jacob P. Thyssen, Kristian Reich, et al.. (2020). Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. Journal of the European Academy of Dermatology and Venereology. 35(2). 476–485. 110 indexed citations

13.

Beis, Daniel, et al.. (2015). Brain serotonin deficiency leads to social communication deficits in mice. Biology Letters. 11(3). 20150057–20150057. 32 indexed citations

14.

Holzwarth, Katrin & Thomas D. Meyer. (2006). The dysregulation of the “Behavioural Activation System”: An independent dimension. Personality and Individual Differences. 41(2). 319–328. 17 indexed citations

15.

Peters, Thorsten, Anca Sindrilaru, Boris Hinz, et al.. (2005). Wound‐healing defect of CD18−/− mice due to a decrease in TGF‐β1 and myofibroblast differentiation. The EMBO Journal. 24(19). 3400–3410. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact